You are here

  • Home
  • Archive
  • Volume 80, Issue 4
  • Response to: ‘Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Carbillon et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Carbillon et al
  1. Maximilian F Konig1,
  2. Milena Gianfrancesco2,
  3. Jinoos Yazdany2,
  4. Philip C Robinson3
  1. 1 Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  2. 2 Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA
  3. 3 Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
  1. Correspondence to Dr Maximilian F Konig, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; konig{at}jhmi.edu; Dr Philip C Robinson, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia; philip.robinson{at}uq.edu.au

https://doi.org/10.1136/annrheumdis-2020-217990

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Carbillon et al for their correspondence.1 The use of hydroxychloroquine (HCQ) in pregnant women with systemic lupus erythematosus (SLE) is not controversial.2 3 Similar to its primary role in the prophylaxis and treatment of SLE, discontinuation of HCQ in pregnancy has been linked to increased disease activity and glucocorticoid use in women with lupus.4–6 Given its benefit and preferable safety profile, the continuation of baseline HCQ therapy in pregnant women with lupus is recommended to maintain disease remission,2 3 regardless of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) status. In contrast, there is currently no evidence to suggest that baseline use of HCQ in pregnant women with lupus is protective of SARS-CoV-2 infection or severe COVID-19.

    The authors adequately summarise our findings …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Twitter @MaxKonigMD, @philipcrobinson

    • Collaborators COVID-19 Global Rheumatology Alliance (full list of collaborators at https://rheum-covid.org/about/)

    • Contributors All authors contributed to data interpretation, writing and final approval of the manuscript.

    • Funding This study was funded by National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR048522).

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles